DURECT Corporation Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 7 Calls Today's Calls

Call Details DURECT Corporation Earnings Conference Call (Q1 2008) Wed, May 7, 2008, 4:30 pm Eastern Listen to the archived event audio About DURECT Corporation (NasdaqGM:DRRX) Durect Corporation, a specialty pharmaceutical company, engages in developing pharmaceutical products based on proprietary drug delivery technology platforms. Its products under Phase II clinical trials include POSIDUR, a release injectable to deliver bupivacaine, an off-patent anesthetic agent; TRANSDUR-Sufentanil, a transdermal sufentanil patch that uses TRANSDUR delivery system to deliver sufentanil, an opioid medication; and ELADUR, a transdermal bupivacaine patch, which uses TRANSDUR transdermal technology and provides continuous delivery of bupivacaine for up to three days from a single application. The company’s product portfolio also comprises CHRONOGESIC pain therapy system, an osmotic implant that delivers sufentanil for an extended duration. In addition, it offers osmotic pumps used in laboratory research; and conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies, as well as designs, develops, and manufactures biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products. The company has a development and commercialization agreement with Voyager to develop and commercialize Memryte, which uses the DURIN implant system to deliver the peptide leuprolide acetate to treat Alzheimer’s disease based on Voyager’s patented method of treatment. Further, it involves in research programs in various diseases and disorders of the central nervous system, including schizophrenia and attention deficit/hyperactivity disorder, as well as in the areas of cardiovascular disease, including congestive heart failure. Durect Corporation was founded in 1998 and is based in Cupertino, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings